Banerjee, A., Jakacki, R. I., Onar-Thomas, A., Wu, S., Nicolaides, T., Young Poussaint, T., . . . Fouladi, M. (2017). A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: A Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol.
Stile di citazione ChicagoBanerjee, Anuradha, et al. "A Phase I Trial of the MEK Inhibitor Selumetinib (AZD6244) in Pediatric Patients With Recurrent or Refractory Low-grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study." Neuro Oncol 2017.
Citazione MLABanerjee, Anuradha, et al. "A Phase I Trial of the MEK Inhibitor Selumetinib (AZD6244) in Pediatric Patients With Recurrent or Refractory Low-grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study." Neuro Oncol 2017.